Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 3/20 | 0.38 |
| ▸ | GABRD | O14764 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.38 |
| ▸ | GABRE | P78334 | 3/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142097 | 0.79 | PHLPP2 (0.46) | HTR2CROCK2SMN1; SMN2MLYCDRAD52 | |
| SCHEMBL10256427 | 0.77 | HRH3 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20878635 | 0.76 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11446223 | 0.74 | CHRNA7 (0.46) | HTR2C | |
| SCHEMBL7830726 | 0.74 | MEN1 (0.45) | HTR2CROCK2SMN1; SMN2MLYCD | |
| SCHEMBL11446658 | 0.73 | HTR2C (0.47) | HTR2CGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11454666 | 0.72 | ACHE (0.46) | HTR2CROCK2SMN1; SMN2MLYCDRAD52 | |
| SCHEMBL2276155 | 0.72 | MMP2 (0.45) | MLYCD | |
| SCHEMBL3692845 | 0.72 | MAPT (0.46) | HTR2CROCK2SMN1; SMN2MLYCDKDM4E | |
| SCHEMBL18457436 | 0.72 | MEN1 (0.55) | HTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | HTR2C 361/4885GABRP 2544/4885GABRD 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.